詳細
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
特異性
Clone 2D10 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects J kappa-recombination signal-binding protein (RBPJ). It targets an epitope within 19 amino acids from the N-terminal region.
免疫原
KLH-conjugated linear peptide corresponding to 19 amino acids from the N-terminal region of human J kappa-recombination signal-binding protein (RBPJ).
アプリケーション
Quality Control Testing
Evaluated by Western Blotting in NIH3T3 cell nuclear extract.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected RBPJ in NIH3T3 cell nuclear extract.
Tested applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected RBPJ in HeLa cell nuclear extract.
Flow Cytometry Analysis: 0.1 μg from a representative lot detected RBPJ in one million Raji cells.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected RBPJ in A431 and C6 cells.
Affinity Binding Assay: A representative lot of this antibody bound RBPJ peptide with a KD of 3.1 x 10-7 in an affinity binding assay.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected RBPJ in human stomach and human liver tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Evaluated by Western Blotting in NIH3T3 cell nuclear extract.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected RBPJ in NIH3T3 cell nuclear extract.
ターゲットの説明
Recombining binding protein suppressor of hairless (UniProt: Q06330; also known as CBF-1, J kappa-recombination signal-binding protein, RBP-J kappa, RBP-J, RBP-JK, Renal carcinoma antigen NY-REN-30) is encoded by the RBPJ (also known as IGKJRB, IGKJRB1, RBPJK, RBPSUH) gene (Gene ID: 3516) in human. RBP-J is a transcriptional regulator that plays a key role in Notch signaling. It acts as a transcriptional repressor when it is not associated with Notch proteins. It associates with several transcriptional co-repressors in the absence of Notch intracellular domain (NICD). Upon activation, following cleavage by -secretase, NICD translocates to the nucleus and forms a transcriptional activation complex with RBPJ. This complex in turn recruits other co-activators and complex components, leading to regulated target gene expression. Genome-wide ChIP-seq profiling reveals both overlapping and non-overlapping chromatin-binding sites occupied by RBPJ and Notch1. Murine RBPJ-only sites are shown to be highly enriched for imputed REST (a DNA-binding transcriptional repressor) sites, whereas human RPBJ-only sites lack REST motifs and are more enriched for imputed CREB sites. Dysregulated RBPJ-dependent gene expression is seen in B-cell tumors associated with Epstein-Barr virus (EBV) and a majority of T-lymphoblastic leukemia/lymphoma (TLL) tumors having somatic Notch1 gain-of-function mutations. Mutations in RBPJ gene are known to cause Adams-Oliver syndrome 3, a disorder characterized by the congenital absence of skin and limb defects. This ZooMAbZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Hassed, SJ., et al. (2012). Am. J. Hum. Genet. 91(2); 391-395; Miele, L. (2011). Proc. Natl. Acad. Sci. USA. 108(36); 14715-14716).
物理的形状
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
再構成
300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
保管および安定性
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
法的情報
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.